Open AccessResponse of diabetic papillopathy to intravitreal bevacizumab
Author(s) -
Hassan Al-Dhibi,
Arif O. Khan
Publication year - 2011
Publication title -
middle east african journal of ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.357
H-Index - 25
eISSN - 0975-1599
pISSN - 0974-9233
DOI - 10.4103/0974-9233.84056
Subject(s) - medicine , bevacizumab , ophthalmology , diabetes mellitus , surgery , chemotherapy , endocrinology
Diabetic papillopathy is an uncommon hyperemic optic disc swelling that occurs in patients with long-standing diabetes, is typically self-resolving with minimal effect on vision, and is likely ischemic in origin. The purpose of the current report is to document the response of diabetic papillopathy to intravitreal injection of bevacizumab (Avastin, Genentech Inc, San Francisco, California, USA), a humanized monoclonal antibody to vascular endothelial growth factor.